AbbVie

YTD

ALL

Trade AbbVie 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.

CEO

Robert A. Michael

CEORobert A. Michael

Employees

55,000

Employees55,000

Headquarters

North Chicago, Illinois

HeadquartersNorth Chicago, Illinois

Founded

2011

Founded2011

Employees

55,000

Employees55,000

ABBV Key Statistics

Market cap

335.46B

Market cap335.46B

Price-Earnings ratio

80.01

Price-Earnings ratio80.01

Dividend yield

3.40%

Dividend yield3.40%

Average volume

8.25M

Average volume8.25M

High today

$193.00

High today$193.00

Low today

$186.67

Low today$186.67

Open price

$187.03

Open price$187.03

Volume

5.52M

Volume5.52M

52 Week high

$218.66

52 Week high$218.66

52 Week low

$163.81

52 Week low$163.81

ABBV News

TipRanks 16h

Pfizer and AbbVie Advance Pediatric Infection Study with ATM-AVI

Pfizer Inc ((PFE)), Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take adv...

TipRanks 5d

AbbVie’s Forecasts Lower Q2 EPS on R&D Costs

AbbVie (ABBV) expects a $0.42 drop in second-quarter earnings per share (EPS), driven by a hefty $823 million pre-tax expense tied to acquired research and deve...

TipRanks 6d

AbbVie’s XEN63 Gel Stent Study: A New Hope for Glaucoma Treatment?

Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks P...

Analyst ratings

60%

of 30 ratings

Buy

60%

Hold

40%

Sell

More ABBV News

TipRanks 6d

AbbVie’s Pediatric Crohn’s Disease Study: A Potential Game-Changer?

Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks P...

People also own

Based on the portfolios of people who own ABBV. This list is generated using Robinhood data, and it’s not a recommendation.